CEPI will provide up to US$40 million in initial funding to support the development of mRNA-vaccine candidates against Lassa Fever virus
Approval based on HIMALAYA Phase III trial results which showed single priming dose of Imjudo added to Imfinzi reduced risk of death by 22% vs. sorafenib
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.
Submission based on QuANTUM-First results showing quizartinib plus chemotherapy significantly improved overall survival compared to chemotherapy alone
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
Micafungin for Injection had annual sales of US $99 million in the United States according to IQVIA data
A MoU was signed between Ministry of Ayush and Ministry of Tribal Affairs to collaborate in Ayush sector
The newest facility has all the core specialties like Obstetrics and Gynaecology, Orthopaedics, Neurology, Cardiology, Paediatrics, General Surgery, and Urology
Subscribe To Our Newsletter & Stay Updated
